Lanreotide
As of the edition of 20 October 2026, Lanreotide is a protein: marketed, first approved in 2001 (FR); acts on SSTR2 and SSTR5.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2012
- Kind
- Protein
- Brand name
- Somatuline Depot
- First approved
- 24 July 2001 (FR)
- Approvals on record
- 16 in 6 regions
- Holder of the most recent approval
- Invagen Pharmaceuticals; 4 holders in all
- Registered trials
- 72, 11 stopped early
- Disease areas
- Cancer; Hormones; Bones, joints and muscles; Nervous system; Digestive system; Inherited and neonatal
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
6 company-target rows on route B because of this drug.
Companies on route B for this drug
In the product6 company-target rows are on route B because of Lanreotide.
See the 6 company-target rows on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 8 | 7 | 0 | 1 |
| Phase 1 | 2 | 0 | 0 | 1 |
| Phase 2 | 23 | 14 | 2 | 4 |
| Phase 3 | 27 | 18 | 2 | 4 |
| Phase 4 | 12 | 9 | 0 | 1 |
| All trials | 72 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Ipsen | Applicant | 2006 to now |
| Teijin Pharma | Applicant | 2012 to now |
| Invagen Pharmaceuticals | Applicant | 2021 to now |